Now I have enough information to write the comprehensive final review. Let me synthesize all findings.Now I have everything I need for the final review.

---

## Summary

ProtEx is a retrieval-augmented protein function prediction method that, for each query sequence and candidate label, retrieves label-conditional positive and negative exemplar sequences via BLAST and conditions a T5-based Transformer model on them for binary classification. The approach is supported by a novel multi-sequence pretraining objective trained over sequence pairs with similarity score prediction. Evaluated across EC, GO, and Pfam prediction tasks on six distinct dataset splits, ProtEx consistently outperforms both BLAST and prior neural methods, with particularly compelling gains for rare classes and out-of-distribution sequences on Pfam.

---

## Strengths

- **Consistent state-of-the-art across six evaluation settings** (Tables 2–5): ProtEx outperforms BLAST, ProteinInfer, CLEAN, and structure-aware models (ESM-GearNet, PST, ProtST) on random EC, clustered EC, random GO, clustered GO, NEW-392, Price-149, PDB EC, and clustered Pfam. The breadth of evaluation is notable and increases credibility of the core claim.

- **Rare-class gains on Pfam (Figure 5)**: ProtEx maintains ~0.9 family accuracy even for families with ≤17 training examples, while ProtTNN and ProtENN drop markedly in that regime. This is the clearest validation of the paper's central motivation—retrieval-augmented conditioning enables generalization to low-data labels—and the evidence is direct and visual.

- **Precision-recall dominance (Figure 4)**: On the clustered EC and GO splits, ProtEx uniformly dominates BLAST across the full precision-recall curve, not just at one operating point. This is a stronger form of validation than comparing single F1 numbers.

- **Generalization to unseen labels (Table 6)**: ProtEx matches or exceeds BLAST even on labels withheld entirely during fine-tuning, and a supplemental ablation shows only minimal degradation when candidate labels are removed from model input, indicating the model learns to exploit exemplar sequences rather than memorize class-to-label mappings.

- **Pretraining ablation (Table 7)**: The multi-sequence pretraining yields consistent gains over single-sequence pretraining, and no pretraining causes a large drop (0.912 vs 0.958), validating that the proposed pretraining strategy matters.

- **Exemplar sampling analysis (Figure 6)**: The insight that geometric or uniform sampling during training aligns the train/eval similarity distribution and reduces out-of-distribution degradation is a practical and well-quantified contribution.

---

## Weaknesses

### Fatal
None.

### Major

- **Pfam "no exemplars" ablation uses a fundamentally different model paradigm.** The paper discloses (Section 4.4): *"For the no exemplar ablation, we found that predicting a binary label without exemplars generalizes poorly when the number of classes is large, and so we instead finetune our pretrained checkpoint to predict the class label as a string given the sequence."* The reported 16-point gap (ProtEx 92.6% vs. no-exemplars 76.3%) therefore conflates the effect of exemplar conditioning with a change in the output space, inference mechanism, and training objective. The core ablation on the paper's largest and most impressive benchmark does not isolate the mechanism of interest. It is plausible that much of the gap stems from binary classification being inherently harder than string prediction at this scale (17,929 classes), not from the absence of exemplars per se. A clean ablation—a binary-classifier variant without exemplars—is needed to establish the actual contribution of exemplar conditioning on Pfam.

- **ProtR is missing from all results tables.** ProtR (Zhang et al., 2024), explicitly discussed in Section 2 as the most directly related neural retrieval approach for protein function, is never compared in Tables 2–5. This leaves the claim of state-of-the-art status among retrieval-augmented neural methods unsubstantiated against its closest competitor. The paper does not explain the omission (e.g., whether ProtR evaluated on different benchmarks).

### Minor

- **Exemplar contribution is negligible on NEW-392 and Price-149.** Table 3 shows ProtEx (no exemplars) = 0.926/0.839 versus full ProtEx = 0.932/0.842 — a delta of 0.006 and 0.003, respectively. The large improvement over BLAST and CLEAN on these benchmarks (0.788→0.932, 0.691→0.842) thus appears to be driven primarily by pretraining and fine-tuning rather than by exemplar conditioning. The paper's narrative consistently attributes performance to exemplar conditioning, but on these important temporal/experimental splits the mechanism is not exemplar retrieval. This deserves explicit acknowledgment.

- **Pretraining contribution is small relative to its billing.** Table 7 shows: single-sequence pretraining = 0.952, pair pretraining w/o score = 0.956, pair pretraining w/ score = 0.958. The multi-sequence pretraining aspect—presented as a "key contribution"—contributes 0.004–0.006 F1 on top of standard single-sequence pretraining, though the overall pretraining vs. no pretraining gap (0.046) is meaningful. The paper's framing slightly oversells the multi-sequence pretraining's incremental value.

- **BLAST-dependency limits the dark proteome claim.** Candidate labels $\hat{\mathcal{L}}_x$ are derived entirely from BLAST hits (Section 3.1). The introduction explicitly motivates the work using the "dark proteome"—sequences dissimilar from any characterized protein—yet the paper never reports the fraction of test queries for which BLAST finds no hits, nor does it analyze behavior in the zero-hit regime. The clustered Pfam results (sequences with <25% identity) partially address this, but the hardest case is not studied.

### Trivial

- Pretraining ablations (Table 7) are only reported on the clustered EC development set. It is unclear whether the same relative ordering holds for GO or Pfam, where label structure and similarity distributions differ substantially.

---

## Nice-to-Haves

- A qualitative case study showing how ProtEx uses exemplars (e.g., downweighting spuriously similar but functionally different exemplars) would clarify what the model is actually learning.
- Quantify what fraction of true labels fall outside the BLAST-retrieved candidate set $\hat{\mathcal{L}}_x$—this upper-bounds ProtEx recall and is never reported.
- Extend retrieval beyond the training set (e.g., UniRef90) to better serve the dark-proteome use case described in the introduction; the paper mentions this as future work.
- Report inference time relative to BLAST in the main text, not just appendix, given the potentially large per-query cost (~45 forward passes for GO).

---

## Removed Points

*These points are flagged to be removed, treat them with caution.*

- **"ProtR cannot be independently verified"** — Removed per hard rule: if the paper cites it, it exists. The weakness about ProtR is kept only as a missing comparison, not a reproducibility concern.

- **"Inference cost is prohibitive"** — The paper openly addresses computational cost in Section 5, cites FiD as a path forward, and argues accuracy improvements justify cost in some applications. This is reasonable scope management, not a flaw. Noted as a nice-to-have in the main text.

- **"PDB EC comparison is unfair to structure-aware models"** — Removed per hard rule: the asymmetry (structure-aware models have structural input advantage) favors the baselines, not the authors. If ProtEx beats them without structure, this is a stronger point, not a weaker one.

- **"The Pfam retrieval system differs from BLAST used elsewhere"** — The paper clearly explains this choice (Section 4.4: scale, parallelizability) and provides analysis of its properties. This is a reasonable engineering decision, not a methodological flaw.

- **"Pretraining ablations not shown on GO/Pfam"** — Moved to Trivial; this is a minor incompleteness.

- **"Inference requires up to |L_x| forward passes"** — Mentioned in nice-to-haves; inference cost is acknowledged and mitigated in the paper. Not a weakness per se.

- **"Generalization to unseen labels is just replicating BLAST"** (Harsh critic, Section 4.5) — Removed as a strawman. ProtEx actually *outperforms* BLAST on unseen labels (Table 6: EC 0.970 vs. 0.964, GO 0.839 vs. 0.816), and the mechanism (learned aggregation from exemplars vs. raw label transfer) is genuinely different.

- **"ProtENN ensemble vs. ProtEx single model"** — The paper reports single-model ProtEx vs. ProtTNN ensemble and still wins. Any concern here favors the baselines, not the authors.

---

## Novel Insights

The paper's most practically novel observation is the exemplar sampling mismatch: deterministic top-k retrieval at training time creates a distributional mismatch with inference time on clustered splits (where query-to-exemplar similarity is lower), and correcting this with uniform or geometric sampling closes most of the distributional gap and substantially improves out-of-distribution generalization. This is a transferable insight for any retrieval-augmented learning system deployed on clustered or temporal splits and goes beyond the paper's own contribution by providing a general recipe for managing train-eval distribution shift in retrieval-augmented models.

---

## Suggestions

1. **Fix the Pfam ablation**: Implement a binary-classifier variant of ProtEx without exemplars (e.g., restrict to the top-1 candidate label and classify without exemplar context). This is the minimum needed to isolate the exemplar effect on Pfam. Alternatively, explicitly reframe the ablation as comparing inference paradigms rather than exemplar presence.
2. **Add ProtR comparison**: Even a single-dataset comparison (clustered EC or clustered GO) against ProtR would establish ProtEx's standing relative to the most closely related prior method.
3. **Report BLAST hit coverage**: Add a table or plot showing the distribution of BLAST hit counts on test sequences for each split, highlighting behavior on zero-hit queries.
4. **Tone down pretraining framing**: In the abstract/intro, describe multi-sequence pretraining as "an improved variant" rather than a standalone "novel contribution" given its 0.004–0.006 incremental F1 gain over single-sequence pretraining.

---

## Score and Decision

**Calibration anchors:**

- *ReNovo* (retrieval-based bioinformatics, accepted poster, avg ~6.5): Closest structural analog — retrieval augments a neural model for a bioinformatics task, state-of-the-art results, similar pattern of "unfair comparison" concerns (eventually dismissed). ProtEx is broader in scope (6 benchmarks vs. 2), more methodologically developed, and has a clearer ablation story despite the Pfam issue.

- *ProteinSSA* (protein function prediction, rejected, avg ~5.7): Similar topic but weaker — missed BLAST as a baseline, narrower evaluation, more limited gains. ProtEx is substantially stronger.

- *KARE/BioBridge* (biomedical RAG, accepted, avg 6.3–7): Higher scores partly due to domain novelty (first to apply RAG in clinical predictions) and cleaner ablations. ProtEx's ablation issue on the biggest dataset and the missing ProtR comparison prevent it from reaching this tier.

- *Low-scoring papers* (avg ~2–3, rejected for fundamental methodology issues): Not comparable — ProtEx's results are real and comprehensive.

**Positioning**: ProtEx sits above the rejected protein-function papers and roughly at the ReNovo level (~6.5). The Pfam ablation issue is real and prevents a confident 7 score — it leaves the primary mechanism on the primary benchmark undemonstrated. The ProtR gap is also a meaningful omission. However, the headline results are genuine, the evaluation breadth is commendable, and the rare-class analysis (Figure 5) is compelling independent of the ablation concern.

**Originality**: Good — applying label-conditional exemplar conditioning with multi-sequence pretraining to protein function is a novel integration of retrieval-augmented methods into this domain.  
**Importance**: High — protein function prediction is an impactful problem, and ProtEx advances the state-of-the-art with practical gains for rare classes.  
**Claim support**: Mostly good — SotA results hold across many settings; mechanism claim on Pfam is undersubstantiated due to the ablation issue.  
**Experimental soundness**: Good overall, with one methodological gap (Pfam ablation).  
**Clarity**: Good — the paper is well-organized and clearly written.  
**Value to community**: Strong — the approach is general and the evaluation is rigorous.

**Final score: 6.5** (Accept with minor revisions — the core empirical contributions are sound and the paper deserves publication, but should address the Pfam ablation and ProtR comparison before or at camera-ready stage).

MY FINAL SCORE: <pineapple>6.5</pineapple>
MY FINAL DECISION: <orange>Accept</orange>